Clotrimazole and Betamethasone Dipropionate (Page 3 of 3)
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential of the combination of clotrimazole and betamethasone dipropionate or either component individually.
Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli) and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay.
In a combined study of the effects of clotrimazole on fertility, embryofetal development, and postnatal development, male and female rats were dosed orally (diet admixture) with dose levels of 5, 10, 25, or 50 mg/kg/day from 10 weeks prior to mating until 4 weeks postpartum. No adverse effects on the duration of estrous cycle, fertility, or duration of pregnancy were noted.
Reproductive studies with betamethasone dipropionate conducted in rabbits at doses of 1.0 mg/kg/day by the intramuscular route and in mice up to 33 mg/kg/day by the intramuscular route indicated no impairment of fertility except for dose-related increases in fetal resorption rates in both species.
14 CLINICAL STUDIES
In clinical trials of tinea corporis, tinea cruris, and tinea pedis, subjects treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) showed a better clinical response at the first return visit than subjects treated with clotrimazole cream. In tinea corporis and tinea cruris, the subject returned 3 to 5 days after starting treatment, and in tinea pedis, after 1 week. Mycological cure rates observed in subjects treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) were as good as, or better than, in those subjects treated with clotrimazole cream. In these same clinical studies, patients treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) showed better clinical responses and mycological cure rates when compared with subjects treated with betamethasone dipropionate cream.
16 HOW SUPPLIED/STORAGE AND HANDLING
Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05% (base) is supplied as follows:
NDC 0168-0258-15, 15 gram tubes
NDC 0168-0258-46, 45 gram tubes
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Rx only
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform the patient of the following:
Pregnancy
Advise pregnant women that clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) may increase the risk of having a low birthweight infant and to use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) on the smallest area of skin and for the shortest duration possible [see Use in Specific Populations (8.1)].
Lactation
Advise a woman to use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.2)].
Important Administration Instructions
Inform patients of the following:
- •
- Use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)as directed by the physician. It is for external use only.
- •
- Avoid contact with the eyes, the mouth, or intravaginally.
- •
- Advise patients to report any visual symptoms to their healthcare providers.
- •
- Do not use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) on the face or underarms.
- •
- Do not use more than 45 grams of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) per week.
- •
- When using clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in the groin area, patients should use the medication for 2 weeks only, and apply the cream sparingly. Patients should wear loose-fitting clothing. Notify the physician if the condition persists after 2 weeks.
- •
- Do not use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) for any disorder other than that for which it was prescribed.
- •
- Do not bandage, cover or wrap the treatment area unless directed by the physician. Avoid use of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in the diaper area, as diapers or plastic pants may constitute occlusive dressing.
- •
- Report any signs of local adverse reactions to the physician. Advise patients that local reactions and skin atrophy are more likely to occur with occlusive use or prolonged use.
- •
- This medication is to be used for the full prescribed treatment time, even though the symptoms may have improved. Notify the physician if there is no improvement after 1 week of treatment for tinea cruris or tinea corporis, or after 2 weeks for tinea pedis.
E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747
46254616A
R08/19#52
Patient Information
Clotrimazole (kloe trim’ a zole) and Betamethasone Dipropionate (bay” ta meth’ a sone dye proe’ pee oh nate) Cream USP, 1%/0.05% (base) |
Important information: Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) is for use on skin only. Do not use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in your eyes, mouth, or vagina. |
What is Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)?
|
Before using clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base), tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take other corticosteroid medicines by mouth or use other products on your skin or scalp that contain corticosteroids. |
How should I use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)?
|
What should I avoid while using clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)? Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) should not be used to treat diaper rash or redness. You should avoid applying clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in the diaper area. |
What are the possible side effects of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)? Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) may cause serious side effects, including:
The most common side effects of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) include burning, tingling, rash, swelling, and infections. These are not all the possible side effects of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)?
|
General information about the safe and effective use of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base). Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) for a condition for which it was not prescribed. Do not give clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) that is written for health professionals. |
What are the ingredients in clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base)? Active ingredients: clotrimazole and betamethasone dipropionate Inactive ingredients: purified water, mineral oil, white petrolatum, cetostearyl alcohol, ceteareth-30, propylene glycol, monobasic sodium phosphate monohydrate, and benzyl alcohol as a preservative |
E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747
46254616A
R08/19
#52
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised August 2019
PRINCIPAL DISPLAY PANEL — 15 g Tube
NDC 0168-0258-15
Fougera
CLOTRIMAZOLE and
BETAMETHASONE
DIPROPIONATE CREAM
USP, 1%/0.05% (base)
Rx only
FOR TOPICAL USE ONLY. NOT FOR
OPHTHALMIC, ORAL, OR INTRAVAGINAL
USE. NOT RECOMMENDED FOR PATIENTS
UNDER THE AGE OF 17 YEARS AND NOT RECOMMENDED FOR DIAPER DERMATITIS.
NET WT 15 grams
PRINCIPAL DISPLAY PANEL — 15 g Carton
NDC 0168-0258-15
Rx only
Fougera
CLOTRIMAZOLE and
BETAMETHASONE DIPROPIONATE
CREAM USP, 1%/0.05% (base)
FOR TOPICAL USE ONLY. NOT FOR
OPHTHALMIC, ORAL, OR INTRAVAGINAL
USE. NOT RECOMMENDED FOR PATIENTS
UNDER THE AGE OF 17 YEARS AND NOT RECOMMENDED FOR DIAPER DERMATITIS.
NET WT 15 grams
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE clotrimazole and betamethasone dipropionate cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
Labeler — E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424) |
Revised: 08/2019 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/clotrimazole-and-betamethasone-dipropionate-12/page/3/